In the ongoing quest to combat obesity and diabetes, current pharmacological treatments have often fallen short in delivering sustainable results without causing debilitating side effects. One of the most widely prescribed classes of drugs, GLP-1 receptor agonists, have revolutionized appetite suppression by targeting neurons within the brain’s hindbrain region. However, despite their efficacy in reducing weight and improving glycemic control, these drugs frequently induce nausea and vomiting, leading to treatment discontinuation in about 70% of patients within the first year. Addressing this clinical challenge, a team of researchers led by Professor Robert Doyle from Syracuse University has unveiled a novel approach that shifts the focus from neurons to “support cells” within the brain, heralding a potential new frontier in obesity therapy.
Traditionally, neurons have been regarded as the primary gatekeepers in neurological drug development, particularly in areas controlling essential bodily functions including hunger and satiety. GLP-1 drugs operate by activating specific neurons located in the hindbrain that modulate appetite signals, effectively decreasing food intake. However, these intricate neuronal pathways often evoke unintended peripheral side effects, notably gastrointestinal distress, limiting the usability and tolerability of such treatments. Recognizing this limitation, Doyle’s multidisciplinary group turned their attention to the less-studied glial and astrocytic populations—collectively termed support cells—that appear to have a critical, yet previously underappreciated, role in appetite regulation.
Support cells have often been overshadowed by neurons in neuropharmacology largely because their functions tend to be complex and multifaceted, involving the maintenance of neural environment homeostasis and the modulation of synaptic activity. Nevertheless, this research revealed that these cells are not merely passive bystanders but active participants in producing bioactive peptides that influence feeding behavior. Through sophisticated biochemical assays and in vivo experiments, Doyle’s team identified that certain support cells in the hindbrain synthesize a signaling molecule known as octadecaneuropeptide (ODN). This endogenous peptide exerts potent anorexigenic effects, effectively signaling satiety and reducing hunger drives.
.adsslot_LrAnmQokvs{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_LrAnmQokvs{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_LrAnmQokvs{width:320px !important;height:50px !important;}
}
ADVERTISEMENT
Experimental administration of ODN directly into the hindbrain of rodent models demonstrated significant weight reduction accompanied by improved glucose metabolism. Although efficacious, the direct brain delivery route is clearly impractical for human therapeutics, inspiring the design of a functionally analogous but pharmacokinetically optimized derivative: tridecaneuropeptide (TDN). Unlike its precursor, TDN is engineered to permit systemic administration, similar in ease to widely used injectable medications like Ozempic or Zepbound. Preclinical trials in obese mice and musk shrews have yielded promising outcomes, showing weight loss and enhanced insulin sensitivity while notably lacking the nausea and gastrointestinal upset commonly induced by GLP-1 receptor agonists.
By bypassing the initial neuronal targets and instead acting on the downstream support cells that regulate appetite suppression more directly, this novel strategy represents a biochemical shortcut—one that could significantly truncate the cascade of signaling events responsible for the adverse effects seen in current therapies. Doyle analogizes this approach to entering a marathon midway rather than starting from the beginning, effectively shortening the path to therapeutic benefits and minimizing the systemic burden of side effects. This paradigm shift not only holds promise for improved patient adherence by enhancing tolerability but also opens new avenues for combinational approaches that may allow lower dosing of GLP-1 drugs in future treatment regimens.
The implications of targeting support cells extend beyond mere symptom management; they may contribute to a deeper understanding of the neurochemical architecture underpinning feeding behavior and metabolic control. Unlike neurons, support cells such as astrocytes and glia form a complex network that modulates the extracellular environment and orchestrates neuronal signaling with precision. Interventions designed to manipulate this network could redefine the boundaries of neuromodulation, offering a more selective and refined method of combating metabolic diseases.
This pioneering research has already catalyzed translational efforts with the establishment of CoronationBio, a biotechnology company focused on harnessing ODN derivatives for clinical application. Licensed from both Syracuse University and the University of Pennsylvania, CoronationBio aims to streamline these discoveries from bench to bedside. The company has announced collaborative ventures with pharmaceutical partners to refine molecule optimization, safety profiling, and scalable production, setting the stage for human clinical trials projected for 2026 or 2027. These forthcoming trials will be critical in validating the clinical viability and therapeutic advantages of this novel class of support cell-targeted drugs.
From a pharmacological standpoint, tridecaneuropeptide represents a fundamental shift in drug design philosophy. Most approved therapies for central nervous system conditions target neuronal receptors and synaptic transmission, but the modulation of glial and astrocytic function remains in early stages. By tapping into these auxiliary cellular systems, researchers could unlock a plethora of untapped mechanisms underlying CNS diseases, potentially revolutionizing treatments for not only obesity but other neurologically mediated disorders.
Furthermore, this strategy may have profound metabolic benefits not limited to weight loss but also encompassing insulin sensitivity and glucose homeostasis. Preclinical data hint at improved glucose uptake and regulation following TDN administration, suggesting that this approach addresses core pathophysiological mechanisms of diabetes, potentially reducing the need for polypharmacy and its associated complications. This holistic influence on metabolic health could establish this new class of treatments as a cornerstone of precision medicine tailored to the multifactorial nature of obesity and diabetes.
Beyond the clinical and mechanistic innovations, this research challenges the broader scientific community to reconsider how neurological support cells contribute to systemic physiological processes. It solicits a reevaluation of the brain’s cellular ecosystem in health and disease, emphasizing the significance of an integrated network rather than isolated neuronal functions. This could spur a renaissance in neuroscience research focused on intercellular interactions, peptide signaling, and the nuanced regulation of bodily functions by non-neuronal brain cells.
In summary, the discovery of appetite-suppressing peptides produced by hindbrain support cells and the pharmacological innovation embodied in tridecaneuropeptide could represent a landmark advancement in obesity and diabetes management. By circumventing the neuronal pathways traditionally targeted by GLP-1 drugs, this approach promises to overcome the notorious side effects that undermine patient adherence. If successful in clinical trials, this treatment could redefine therapeutic standards, offering safer, more tolerable options for millions worldwide grappling with metabolic disease.
Ultimately, Doyle and his multidisciplinary team have illuminated a novel cellular target within the brain’s appetite regulatory circuitry, demonstrating that the key to effective weight loss may lie not just within the neurons themselves but in the supportive cellular milieu that sustains their function. This breakthrough underlines the importance of expanding our biological paradigms and integrating chemistry, pharmacology, and neuroscience to develop next-generation medicines tailored for complex human conditions.
Subject of Research:
Obesity and diabetes treatment targeting brain support cells for appetite suppression.
Article Title:
A Novel Support Cell-Targeted Peptide Offers Appetite Suppression Without Nausea.
Web References:
https://artsandsciences.syracuse.edu/people/faculty/doyle-robert/
https://mediasvc.eurekalert.org/Api/v1/Multimedia/4bf69938-c6f6-4fdb-8797-35ce0b33256c/Rendition/low-res/Content/Public
Image Credits:
Syracuse University
Keywords:
Chemistry, Chemical biology, Clinical medicine, Translational medicine, Personalized medicine
Tags: appetite modulation without nauseaappetite suppression mechanismsbrain support cells in weight losscombating obesity and diabetes alternativesgastrointestinal side effects of weight loss drugsGLP-1 receptor agonists and nauseainnovative obesity therapiesneurological drug development for obesityobesity treatment advancementsProfessor Robert Doyle researchsustainable weight loss solutionsweight loss without side effects
